499 related articles for article (PubMed ID: 29157685)
1. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
Parikh PK; Ghate MD
Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
3. Recent Progress in the Development of Small Molecule c-Met Inhibitors.
Lv PC; Yang YS; Wang ZC
Curr Top Med Chem; 2019; 19(15):1276-1288. PubMed ID: 31526339
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present).
Lv PC; Wang ZC; Zhu HL
Curr Med Chem; 2017; 24(1):57-64. PubMed ID: 27804876
[TBL] [Abstract][Full Text] [Related]
5. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
6. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
Accornero P; Pavone LM; Baratta M
Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
[TBL] [Abstract][Full Text] [Related]
7. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
Dussault I; Bellon SF
Anticancer Agents Med Chem; 2009 Feb; 9(2):221-9. PubMed ID: 19199866
[TBL] [Abstract][Full Text] [Related]
8. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
9. Developing Antagonists for the Met-HGF/SF Protein-Protein Interaction Using a Fragment-Based Approach.
Winter A; Sigurdardottir AG; DiCara D; Valenti G; Blundell TL; Gherardi E
Mol Cancer Ther; 2016 Jan; 15(1):3-14. PubMed ID: 26712116
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
12. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates.
Underiner TL; Herbertz T; Miknyoczki SJ
Anticancer Agents Med Chem; 2010 Jan; 10(1):7-27. PubMed ID: 20015007
[TBL] [Abstract][Full Text] [Related]
13. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
[TBL] [Abstract][Full Text] [Related]
15. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
Cui JJ
J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
[TBL] [Abstract][Full Text] [Related]
16. EDITORIAL: Advances in Developing Versatile Tools for the Discovery of Novel Therapeutics.
Hu Y
Curr Top Med Chem; 2017; 17(20):2233-2234. PubMed ID: 28799501
[No Abstract] [Full Text] [Related]
17. c-Met kinase inhibitors: an update patent review (2014-2017).
Zhang QW; Ye ZD; Shi L
Expert Opin Ther Pat; 2019 Jan; 29(1):25-41. PubMed ID: 30474428
[TBL] [Abstract][Full Text] [Related]
18. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H; Rost S; Yauch RL
J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
[TBL] [Abstract][Full Text] [Related]
19. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
20. Targeting MET: why, where and how?
Ghiso E; Giordano S
Curr Opin Pharmacol; 2013 Aug; 13(4):511-8. PubMed ID: 23797036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
